OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION
|
|
- Stanley Owen Russell
- 6 years ago
- Views:
Transcription
1 OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION Debra L. Sietsema, PhD, RN Director, Bone Health Clinical Operations October 5, 2016 OTA NP/PA Course 1
2 Osteoporosis Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture Normal Bone Osteoporotic Bone NIH Consensus Development Panel on Osteoporosis. JAMA. 2001;285:
3 WHO Classification 3
4 Fragility Fracture Resulting from a: Fall from a standing height Spontaneous fracture Establishes osteoporosis diagnosis regardless of DXA results Siris, et al. The clinical diagnosis of osteoporosis. Ost Int. 2014; 25:
5 Shifting the Osteoporosis Paradigm: Bone Strength Bone Density abmd = g/cm 2 vbmd = g/cm 3 Bone Quality Bone Strength Mineralization Bone remodeling Damage accumulation Trabecular connectivity Architecture NIH Consensus Development Panel on Osteoporosis. JAMA. 2001;285:
6 What s the problem? 6
7 7
8 Prevalence of Osteoporosis and Low Bone Mass Americans Age 50 and Above Affected by Osteoporosis/Low Bone Mass, 2010 to 2030 (projected) 80 Osteoporosis Prevalence of Osteoporosis and Low Bone Mass 54 million of 99 million Americans age 50+ (2010) 17% of the ENTIRE U.S. POPULATION (2010) Millions Wright NC, et al. JBMR doi: /jbmr % change from 2010 to 2030 Low Bone Mass Osteoporosis 8
9 Hospitalization Burden for Osteoporotic Fractures and Other Serious Diseases in Older US Women Figure 1. Percent of hospitalizations* for osteoporotic fractures and other serious diseases combined, *Principal diagnosis codes were used to define the outcomes. Singer AJ, et al. Osteoporosis International. 25(4) suppl: ;2014. Singer AJ, et al. Mayo Clinic Proceedings ,
10 Incidence Rates for Vertebral, Wrist, and Hip Fractures in Women After Age Vertebral 30 Annual Incidence per 1000 Women Wrist Hip Age (Years) Wasnich RD. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott; 1999:
11 Incidence Rates for Vertebral, Wrist, and Hip Fractures in Women After Age Vertebral Annual Incidence per 1000 Women Youngest Baby Boomers Largest Baby Boomer Group Wrist Hip Age (Years) Oldest Baby Boomers Wasnich RD. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott; 1999:
12 Incidence Rates for Vertebral, Wrist, and Hip Fractures in Women After Age Annual Incidence per 1000 Women Youngest Baby Boomers Wrist Largest Baby Boomer Group Vertebral Hip Oldest Baby Boomers Age (Years) Wasnich RD. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott; 1999:
13 Distal Radial Fractures The lifetime risk of sustaining a distal radial fracture is about 16% for white women. By age 70, about 20% of women have had at least one distal radial fracture. 13
14 Vertebral fractures 35 to 50% of all women over fifty have at least one vertebral fracture. Between 30-65% are undiagnosed 1 3X risk 3 9X risk Siris, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Ost Int. 2007;18:
15 Proximal Femoral Fractures A 50-year-old white woman is estimated to have a 17.5% lifetime risk of fracture of the proximal femur. 15
16 Proximal Femoral Fractures Incidence increases each decade for all populations. Highest incidence is found among men and women ages 80 or older. 16
17 1 out of 2 Women will have an osteoporotic fracture 17
18 1 in 4 Men will have an osteoporotic fx More likely to have an osteoporotic fracture than to get prostate cancer 80,000 men have a hip fracture annually Men are more likely to die within a year after hip fracture 18
19 Importance to Orthopedics Unique opportunity sentinel event Reduce subsequent fractures Enhance fracture healing Comprehensive, excellent care 19
20 Osteoporotic Disasters 20
21 Osteoporotic Disasters 21
22 Osteoporotic Disasters 22
23 Osteoporotic Disasters 23
24 Osteoporotic Disasters 24
25 Osteoporotic Disasters 25
26 Osteoporotic Disasters 26
27 Advances to Treat these Fractures Locking technology Cephalomedullary nails Ceramics Osteobiologics 27
28 Identified Treatment Gap - NCQA HEDIS Measure % Compliance Beta-blocker after a heart attack 91.4% Breast cancer screening 82.7% Colorectal cancer screening 73.8% Osteoporosis management after a fracture 20.7% NCQA Medical Evaluation HMO Statistics 28
29 Optimal Management of Care Diagnosis of fragility fracture General fracture management Rehabilitation Secondary prevention: Prevent subsequent fx Identify, assess, treat, & evaluate underlying disease Teach & counsel re: condition & lifestyle behaviors Coordinated, comprehensive manner Ganda. Models of care. Ost Int
30 Fragility Fracture? Injury Pattern Mechanism of injury Low trauma Fall from a standing ht or less Fx that occurred during activity Did others involved fx? Risk Assessment Risk factors for: 1 & 2 osteoporosis Fracture Fall No symptoms of low bone mass until fracture. May be 1 st indication of osteoporosis! 30
31 Physical Findings Clinical Presentation indicating increased fracture risk Impaired ambulation Muscle weakness Impaired balance Reduced vision Macular Degeneration Glaucoma Bifocals Orthostatic hypotension Clinical presentation indicating signs of prior fractures Loss of height Kyphosis Chest deformity Protuberant abdomen Rib-pelvis overlap 31
32 Key Risk Factors for Fractures (RR 2) Age BMD Prior fragility fx Family hx of fragility fx Kanis. Ost Int. 2005; 16 32
33 Causes of Secondary Osteoporosis Endocrine Disorders affecting bone metabolism Menopause < age 45 Hypercalcuria with or without renal stones Hypogonadism Hyperparathyroidism Hyperthyroidism Cushing s syndrome Diabetes (types 1 and 2) Acromegaly Osteogenesis Imperfecta 33
34 Causes of Secondary Osteoporosis Drugs affecting bone quality Excess/length of time on glucocorticoids Excess thyroid hormones Anticoagulants (heparin) GnRH agonists Anticonvulsants Aromatase inhibitors Thiazolidinediones Opiates Cyclosporine Chemotherapy Alcohol Loop diuretics PPI long term use 34
35 Secondary Causes of Osteoporosis GI Tract Disorders Malabsorption Gastrectomy Inflammatory bowel disease Celiac disease Intestinal bypass surgery Primary biliary cirrhosis Pancreatic insufficiency Hepatitis B, C Bone Marrow Based Disorders Multiple myeloma Hemolytic anemia, hemoglobinopathies Myelo-and lymphoproliferative disorders Skeletal metastases (diffuse or localized) Gaucher s disease Mastocytosis 35
36 Secondary Causes of Osteoporosis Inflammatory Disorders RA SLE Ankylosing spondylitis Polymalgia rheumatica Vasculitis Other Propensity to fall Immobilization COPD Chronic renal failure AIDS/HIV Organ transplantation Anorexia / Bulemia Malignancy 36
37 Other Significant Risk Factors Vitamin D insufficiency History of missed menses/estrogen deficiency Smoking Excessive alcohol intake Sedentary lifestyle Environmental risks for fall Collagen deficiency Hypermobility / flexibility 37
38 Clinical Approach to Managing Osteoporosis Assessment Detailed osteoporosis risk factor hx r/t fx & falls Physical exam Diagnostic studies 10-year probability of fx (FRAX) Ultimate Goal Prevent fractures Plan Mutual plan 38
39 Clinical Approach to Managing Osteoporosis Implement Nonmedical interventions Modify risk factors PT/OT Psychosocial support Supplements Prescriptive therapies Evaluate Lifestyle changes Rx Compliance Diagnostic studies Vertebral imaging Fracture occurrence 39
40 Suggested Laboratory Tests Complete blood count Serum chemistry studies Serum 25-hydroxyvitamin D ipth Bone turnover markers CTX & P1NP TSH Testosterone 1, 25 Vitamin D 24 hr urine for calcium Phosphorus Watts NB, et al. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis Endocr Pract. 2010;16(suppl 3):1-37. Cosman, et al. Clinician s guide to prevention and treatment of osteoporosis. Ost Int. 2015; 26:
41 Other Laboratory Tests Lab Test Erythrocyte sedimentation rate Urinary cortisol or other tests Serum protein electrophoresis (SPEP) and light chains Tissue transglutaminase antibodies Purpose Malignancy or inflammatory disease Adrenal hypersecretion Myeloma Celiac disease 41
42 Pharmacological Treatment Guidelines Postmenopausal women and men age 50 and older presenting with one of the following: Fracture T-Score - A vertebral or hip fracture - T-score -2.5 at the femoral neck, total hip, or lumbar spine by DXA FRAX - 10-year probability of a major fracture 20% - 10-year probability of a hip fracture 3% Cosman, et al. Clinician s guide to prevention and treatment of osteoporosis. Ost Int. 2015; 26:
43 Treatment Guidelines: Post-menopausal Women And Men 50 Assess Risk Factors and Measure BMD if Patient Has Risk Factors T-score between -1.0 and -2.5 Hip or Vertebral Fractures or T-score -2.5 (Spine, Femoral Neck or Total Hip) FRAX 10-year Probability of Hip Fracture 3% or Probability of All Major Fractures 20% 43
44 Medications for Osteoporosis Inhibit Bone Resorption Bisphosphonates Alendronate (Fosamax) Risedronate (Actonel, Atelvia) Ibandronate (Boniva) Zolendronate (Reclast) Monoclonal antibody Denosumab (Prolia) SERM Raloxifene (Evista) Other Estrogen (various) Calcitonin(Miacalcin, Fortical) Stimulate Bone Formation Anabolic Teriparatide (Forteo) 44
45 FDA Approved Medications: Evidence for Fracture Reduction Medication BMD Vertebral Fx Nonvertebral Fx Hip Fx Alendronate X X * X Risedronate XX X X * Ibandronate XX X No effect No effect Zoledronic acid XX X X X Denosumab XXX X X X Raloxifene X X No effect X Teriparatide XXX X X X * Evidence for effect, but not FDA approved indication 45
46 Challenges of Osteoporosis Rx Success = absence of fracture $$$ Other costs of treatment: Nuisance of taking another medication Reminder of illness/condition Worry about consequences of therapy Adverse effects of treatment 46
47 Atypical Femoral Fractures With every 50 hip fractures prevented with bisphosphonates, 500/1000 women will suffer a fracture without treatment 1 atypical femoral fracture may result. Out of 1,000 people on bisphosphonates for 5 years, < 1 will have an atypical fx (.16/1000) & < 1 will have osteonecrosis of the jaw (.01/1000).
48 Adherence & Persistence Patient Pain & Disability Teachable Moment Begin regimen early Purposes Enhance fracture healing Prevent subsequent fractures Treatment Team Fracture liaison service (FLS) Recognizable face Consistent message Coordinated or Separate appointments Education, counseling and guidance Assure follow-up 48
49 Treatment: Summary Safe and effective therapies are available Anti-remodeling (antiresorptive) agents Prevent bone loss and preserve architecture Reduce the risk of vertebral fractures (all agents) Alendronate, risedronate, zoledronic acid and denosumab reduce the risk of nonvertebral and hip fractures Bone building (anabolic) agent: (teriparatide) Increases bone density and size Improves quality of bone Reduces the risk of vertebral and nonvertebral fractures New Drugs: Abaloparatide (anticipated Q2 2017): anabolic Romosozumab (anticipated late 2017): antisclerostin antibody Patient factors determine the most appropriate drug to use 49
50 Treatment: Summary, continued BMD Change Doesn t Fully Predict the Reduction in Fracture Risk Fracture Risk Anti-remodeling treatment decreases fracture risk more rapidly and to a larger extent than one would predict from the relatively small changes in BMD Fracture protection can be observed in the absence of a significant change in BMD Fracture protection persists even when the BMD reaches a plateau BMD stability does not mean nonresponse 50
51 Treatment: Summary, continued The fracture risk is determined by the complex interactions among bone mineral density (BMD), bone quality, and trauma Contemporary pharmacologic treatments will typically reduce vertebral fracture risk by 30%-70%, with smaller reductions in non-vertebral fracture risk No pharmacologic treatment is likely to reduce fracture risk to zero, in part because of the inability to eliminate trauma There are a number of promising pharmacologic agents with most of the emphasis to be placed on the development of novel anabolic agents 51
52 Integrate Own The Bone Program: Ten Important Measures to Achieve Success NUTRITION COUNSELING* 1. Calcium supplementation 2. Vitamin D supplementation PHYSICAL ACTIVITY COUNSELING* 3. Exercise, especially weight-bearing and muscle strengthening 4. Fall prevention education LIFESTYLE COUNSELING* 5. Smoking cessation 6. Limiting excessive alcohol intake PHARMACOLOGY* 7. Pharmacology for the treatment of osteoporosis TESTING* 8. DXA to test bone mineral density COMMUNICATION 9. Physician referral letter 10. Follow-up notes and educational materials provided to patient *Unless contraindicated. Measures listed here are consistent with recommendations from the National Osteoporosis Foundation, the Centers for Medicare & Medicaid Services, the Joint Commission, the World Health Organization, and the American Medical Association. 52
53 Rewards of Osteoporosis Treatment Reduction in the risk of fracture Reduction in pain and disability Preservation of independence Reduction in height loss Positive effect on mortality (?) Positive effect of being proactive Positive effect on BMD Decrease in subsequent fractures Unique benefit to community 53
54 Bone Health Across the Lifespan 54
55 Keep Life in Motion! 55
56 Questions? 56
Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationPrevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist
Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Prevalence of Osteoporosis 1.5 million fractures annually in the U.S. Overall lifetime risk for an osteoporotic fracture is about
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationWHAT NONPHYSICIAN PROVIDERS CAN DO FOR YOUR FRAGILITY FRACTURE SERVICE
WHAT NONPHYSICIAN PROVIDERS CAN DO FOR YOUR FRAGILITY FRACTURE SERVICE Debra L. Sietsema, PhD, RN October 7, 2016 OTA Meeting 1 Disclosures Speaker and Consultant: Lilly USA Committee Member: AOA Own the
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationSarena Ravi MD, MPH Endocrinologist. Franciscan Physicians Network Division of Endocrinology Chicago, IL
Sarena Ravi MD, MPH Endocrinologist Franciscan Physicians Network Division of Endocrinology Chicago, IL Definition & Diagnosis of Osteoporosis Management of Osteoporosis in all Populations Long term Management
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationConflict of Interest. Disclosures: Learner Outcome
Conflict of Interest -primary prevention and secondary fracture prevention for the Advanced Practice Nurse Anne Lake, DNP, ONP-C, FNP-C, CCD I hereby certify that, to the best of my knowledge, no aspect
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationFragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service
Fragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service Objectives Define Fragility Fractures and discuss importance of identification
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationPrevention of Osteoporotic Hip Fracture
Prevention of Osteoporotic Hip Fracture Dr Law Sheung Wai 8th July 2007 Associate Consultant Spine team / Orthopedic Rehabilitation Department of Orthopedics and Traumatology NTE Cluster 1 Objectives Problems
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationDISCLAIMER DO NOT DISTRIBUTE
DISCLAIMER The information contained in this presentation is not intended as a substitute for professional medical advice, diagnosis, or treatment. It is provided for educational purposes only. You assume
More informationOsteoporosis Physician Performance Measurement Set. October 2006
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationHealthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C
Healthy Bones: Osteoporosis Management Laurel Short, MSN, FNP-C Disclosure I have no current affiliation or financial interest with any grantor or commercial interests that may have direct interest in
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationSteven W. Ing, M.D., MSCE Assistant Professor of Internal Medicine
Osteoporosis Steven W. Ing, M.D., MSCE Assistant Professor of Internal Medicine Department of Internal Medicine Division of Endocrinology, Diabetes, & Metabolism Ohio State University Medical Center Case
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationOsteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationCOURSE OUTLINE - Module I
Module I MEDICAL DISCLAIMER The information in this program is for educational purposes only. It is meant to as a guide towards health and does not replace the evaluation by and advice of a qualified licensed
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationDivision of Nephrology, Bone and Mineral Metabolism
Osteoporosis and fractures Measurement of bone density Diagnosis of osteoporosis Bone biopsy Newer therapies and challenges Osteoporosis: Definition Normal Bone Osteoporotic Bone NIH Definition:..A skeletal
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More information2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications. Outline. The Process. Osteoporosis Diagnosis NEW CLINICAL DEFINITION
2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications Steven M. Petak MD, JD, MACE, FACP Associate Clinical Professor Weill-Cornell Medical College Division Head and Chief of Endocrinology
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationOsteoporosis. A Silent Killer. David A. Chappell, MD Endocrinology Private Practice Petaluma, California
Osteoporosis A Silent Killer David A. Chappell, MD Endocrinology Private Practice Petaluma, California Relevant Disclosures Speakers Bureau Astra Zeneca Boehringer Ingelheim AACE/ACE Guidelines American
More informationWhat is Osteoporosis?
What is Osteoporosis? Systemic skeletal disease characterized by: low bone mass (T-score < -2.5) biochemically normal bone microarchitectural deterioration of bone tissue Hallmark- Increased bone fragility
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More information